2024
Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, Inman B, Taber A, Nordentoft I, Jensen J, Dyrskjøt L, Lerner S. Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics. IScience 2024, 27: 109179. PMID: 38439961, PMCID: PMC10910238, DOI: 10.1016/j.isci.2024.109179.Peer-Reviewed Original ResearchCarcinoma in situCarcinoma in situ lesionsUrothelial carcinoma in situPapillary tumorsAggressive phenotypeAssociated with carcinoma in situNon-muscle-invasive bladder cancerCarcinoma in situ samplesPD-1-positive cellsImmune marker expressionBladder cancerImmunological landscapeMarker expressionTumorGene signatureMutational heterogeneityImmune characteristicsMutated genesExpression signaturesTargeting mTORHigher expressionTime pointsMutation analysisMultiomic profilingLesions
2023
Genomic Profiling of Urothelial Carcinoma <I>in Situ</I> of the Bladder
Anurag M, Strandgaard T, Kim S, Comperat E, Al-Ahmadie H, Inman B, Dyrskjot L, Lerner S. Genomic Profiling of Urothelial Carcinoma in Situ of the Bladder. EMJ Urology 2023, 11: 41-42. DOI: 10.33590/emjurol/10306009.Peer-Reviewed Original ResearchCarcinoma in situUrothelial carcinoma in situCarcinoma in situ lesionsPapillary tumorsWhole-exome sequencingBladder cancerInvasive cancerMolecular subtypesT cellsFFPE samplesAssociated with carcinoma in situPresence of cytotoxic T cellsProgrammed cell death protein 1Formalin-fixed paraffin-embedded (FFPE) tumorsAssociated with invasive cancerCarcinoma in situ samplesCell death protein 1Detecting carcinoma in situExome sequencingLevels of immune cellsRNA sequencingProbability of disease progressionHigh-grade lesionsRegulatory T cellsCytotoxic T cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply